How Should Medical Research and Life Sciences Companies in Calgary Handle AI?

Last updated: March 2026

Calgary's medical research and life sciences sector is growing, driven by provincial investment, proximity to university research programs, and a cluster of clinical research organizations and pharmaceutical services companies. These companies face a distinct AI challenge that most general guides miss entirely: they handle clinical trial data, patient health information, proprietary pharmaceutical research, and medical imaging, all of which carry regulatory obligations and confidentiality requirements that make consumer AI tools a serious liability. Yet the operational efficiency gains from AI in data collection, report generation, project management, and administrative workflows are too significant to leave on the table. This guide addresses how medical research and life sciences companies in Calgary can adopt AI safely, what the specific risks are, and how to build an AI foundation that satisfies both operational ambitions and regulatory realities.

Why Life Sciences Is Different from Other Industries

Most AI adoption guides are written for companies where the worst consequence of an AI data breach is embarrassment or competitive loss. In medical research, the consequences are materially different.

Clinical research organizations handle data governed by Health Canada regulations, institutional ethics board requirements, and contractual obligations with pharmaceutical sponsors. A researcher who pastes clinical trial data into a consumer AI tool (free ChatGPT, for example) has potentially violated multiple regulatory frameworks simultaneously. The data may be stored on servers with no data processing agreement, in jurisdictions with different privacy laws, and with no guarantee of deletion.

A 2025 Salesforce survey found that 28% of workers use generative AI at work without their employer's knowledge. In a typical professional services company, that shadow AI creates governance risk. In a medical research company, it creates regulatory risk, contractual risk, and potentially patient safety risk. The stakes are categorically higher.

This is compounded by the nature of the data itself. Medical research involves not just text and numbers, but imaging (radiology, pathology, diagnostic imaging), structured datasets from clinical trials, and proprietary analytical methodologies. The AI tools that can add the most value are precisely the ones that need the most careful governance.

The Shadow AI Problem in Medical Research

Solway has spoken with Calgary life sciences companies where the shadow AI problem is already real. In one case, a clinical research company with operations across Calgary, Toronto, and Manitoba discovered that researchers were using consumer AI tools to help with data analysis and report drafting. There was no malicious intent. Researchers were simply trying to work more efficiently with the tools available to them. But there was no AI policy, no approved tool list, and no guidance on what data could or could not be entered into which systems.

The company's leadership recognized the problem immediately: they needed to give their team safe, approved ways to use AI before unguided experimentation created an incident. The challenge was that no one internally had the expertise to evaluate which tools were safe, what configurations were needed, and how to write a policy that addressed the specific data sensitivities of pharmaceutical research.

This is a pattern Solway sees across regulated industries in Alberta: the gap is not awareness (leadership knows AI matters), and it is not willingness (teams want to use it). The gap is structured guidance that accounts for the specific regulatory and data environment of the industry.

What Safe AI Adoption Looks Like in Life Sciences

Safe AI adoption for a medical research company in Calgary requires addressing four layers, each building on the one before it.

Layer 1: AI Policy with Regulatory Alignment

The AI policy for a life sciences company cannot be a generic document borrowed from a tech company template. It must specifically address Health Canada requirements for clinical trial data handling, ethics board obligations, sponsor confidentiality agreements, and provincial privacy legislation.

Solway's AI Policy Framework, the Solway System, provides the structural foundation. It is a 14-component framework across three sections (Role and Purpose, Accountability and Trust, Ethical Use), each calibrated on a sliding scale from caution-oriented to innovation-oriented. For life sciences companies, the data handling and input/output controls sections are calibrated toward the caution end, while the productivity and internal workflow sections can be positioned more aggressively.

The practical output is a Staff Decision Guide: a simple document that answers the question "Can I use AI for this?" for every common scenario a researcher or project manager encounters. Can I use AI to draft an internal project update? Yes. Can I paste clinical trial participant data into ChatGPT? No. Can I use Copilot to summarize a publicly available research paper? Yes. Can I upload sponsor-provided drug efficacy data to an AI tool? No, unless the tool meets specific data residency and processing requirements.

Layer 2: Enterprise-Grade Tools with Data Controls

The tool selection for life sciences companies is more constrained than for general business. Consumer-tier AI tools (free ChatGPT, Google Gemini free tier) are typically unsuitable because they lack data processing agreements, data residency guarantees, and enterprise-grade security controls.

Microsoft Copilot with a Microsoft 365 enterprise license is often the best starting point for Calgary life sciences companies because it operates within the organization's existing Microsoft 365 tenant. Data entered into Copilot stays within the organization's data boundary and is subject to the same compliance controls that govern their SharePoint, Teams, and Exchange environments. For companies already holding Microsoft 365 licenses (as most Alberta businesses do), this means AI adoption does not require a new vendor, a new security review, or a new data processing agreement.

For specialized use cases involving medical imaging or structured clinical data, more targeted solutions may be needed. The key principle is that the AI tool's data handling must meet or exceed the data handling requirements of the underlying data category.

Layer 3: Role-Specific Training

Generic AI training is insufficient for life sciences teams. A researcher handling clinical trial data needs different guidance than a project manager tracking timelines, who needs different guidance than an administrative coordinator managing invoices and communications.

Effective training for a life sciences company covers three domains. First, universal foundations: what AI is, how it works, where it fails, and the general principles of safe use. Second, tool-specific skills: how to use Microsoft Copilot (or the approved tool set) effectively within Outlook, Word, Excel, and Teams. Third, role-specific protocols: what each role can and cannot do with AI, based on the data they handle and the regulatory context they operate in.

Solway's workshops are customized to the industry context. For a medical research company, that means the examples, exercises, and prompt library are drawn from real research workflows rather than generic business scenarios.

Layer 4: Ongoing Governance and Monitoring

AI adoption in a regulated environment is not a one-time event. The tool landscape changes, new capabilities emerge, regulations evolve, and team members join who were not part of the initial training. A sustainable AI program includes periodic policy reviews (at minimum annually), onboarding protocols for new employees, a feedback mechanism for the team to flag new use cases or concerns, and a monitoring approach to ensure approved tools are being used as intended.

For smaller life sciences companies in Calgary (10-50 employees), this does not require a dedicated AI governance function. It requires an identified owner (often an operations leader or compliance officer) and a structured check-in cadence, which can be supported by a fractional AI partner.

The Opportunity Beyond Risk Mitigation

The conversation about AI in life sciences tends to be dominated by risk. But the opportunity side is substantial.

Data collection and cleaning, which consumes enormous researcher time, can be significantly accelerated with AI tools that validate entries, flag anomalies, and format data for analysis. Report generation, from interim study reports to final submissions, can be drafted by AI and refined by experts, cutting writing time by 40-60%. Project management tasks like timeline tracking, resource allocation, and stakeholder updates can be largely automated. Administrative overhead (invoicing, payroll management, HR communications) can be streamlined with the same tools that work for any mid-size business.

The companies that get the foundation right (policy, tools, training, governance) are the ones that can capture these gains without creating the risks that come from unstructured adoption.

The CAPG Advantage for Alberta Life Sciences

Alberta's Canada-Alberta Productivity Grant (CAPG) reimburses employers for up to 50% of eligible training costs. For a life sciences company with 15-30 employees across Calgary and other Alberta locations, this can offset a significant portion of the investment in structured AI training.

Importantly, CAPG eligibility applies to employees based in Alberta. For companies with distributed teams (common in life sciences, where staff may work across Calgary, Edmonton, and other provinces), the training can include all Alberta-based employees. Employees based outside Alberta are not eligible for CAPG but can still participate in the training.

The training must be delivered by an eligible third-party provider. Solway's workshops qualify, and we structure our programs to include the ongoing component (office hours, follow-up sessions) that life sciences companies find most valuable for sustained adoption.

Frequently Asked Questions

Is Microsoft Copilot safe for handling medical research data?

Microsoft Copilot for Microsoft 365 operates within your organization's existing Microsoft 365 data boundary. It does not train on your data, and your data is subject to the same compliance, security, and privacy commitments that apply to your Microsoft 365 tenant. For most clinical research data handling scenarios, this meets the required standard. However, specific sponsor agreements or ethics board requirements may impose additional constraints that should be evaluated case by case.

What is the biggest AI risk for medical research companies?

Shadow AI, meaning employees using unapproved consumer AI tools with sensitive data. This risk exists today at most organizations that have not established a clear AI policy with approved tools and explicit guidance on data handling. The solution is not to ban AI but to provide safe alternatives and clear guidance.

How do we handle AI training for a distributed team across multiple provinces?

Solway delivers training virtually or in hybrid formats that accommodate distributed teams. The content can be standardized across locations while accounting for any province-specific regulatory considerations. For CAPG purposes, only Alberta-based employees are eligible for the grant.

Does our company need a dedicated AI officer?

Not typically at the 10-50 employee scale. What you need is an identified owner for AI governance (this can be an existing operations or compliance role) and a structured framework that makes the day-to-day decisions clear. Solway's Staff Decision Guide is designed for exactly this: it translates the policy framework into simple, actionable guidance that does not require AI expertise to follow.

How is AI being used for medical imaging analysis?

AI-assisted imaging analysis (radiology, pathology, diagnostic imaging) is advancing rapidly but operates under specific regulatory frameworks that differ from general business AI adoption. These use cases typically require specialized, regulated software rather than general-purpose tools like Microsoft Copilot. Our recommendation is to start with the business workflow and administrative use cases (where ROI is immediate and regulatory complexity is lower) and approach clinical imaging use cases as a separate, more specialized initiative.

Can Solway help with AI adoption for medical research companies?

Yes. Solway has experience working with regulated industries including government agencies handling sensitive data (Global Affairs Canada) and organizations with strict confidentiality requirements. We structure our engagements to address the specific data handling, regulatory, and governance needs of each industry. Contact us at solway.ai to discuss your situation.